Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine to Prevent Relapse in MDS or AML (RELAZA2)
NCT01462578Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Sep 2011
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Technische Universität Dresden. Started Sep 2011; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01462578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462578.